EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The role of the microbiota and metabolites in the treatment of pulmonary fibrosis with UC-MSCs: Integrating fecal metabolomics and 16S rDNA analysis

Yukai Luo, Shuang Zhou, Xiaojing Zhang, Yijian Lin, Jun Liu, Wenzhao Cheng iD, Yiming Zeng

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0313989 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Yukai Luo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Key Laboratory of Lung Stem Cells, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Metabolomics, Feces, RNA, Ribosomal, 16S. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Research Group Project of the National Natural Science Foundation of China, Research Project of Jinan Microecological Biomedicine Shandong Laboratory, the Project for Yong and Middle-aged Key Talents in Health Commission of Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pulmonary fibrosis (PF) is a chronic and irreversible interstitial lung disease characterized by a lack of effective therapies. Mesenchymal stem cells (MSCs) have garnered significant interest in the realm of lung regeneration due to their abundant availability, ease of isolation, and capacity for expansion. The objective of our study was to investigate the potential therapeutic role of umbilical cord-derived MSCs (UC-MSCs) in the management of PF, with a focus on the alterations in the gut microbiota and its metabolites during the use of UC-MSCs for the treatment of pulmonary fibrosis, as well as the possible mechanisms involved.

Methods

Bleomycin injection was utilized to establish a mouse model of lung fibrosis, followed by the application of 16S rDNA sequencing and LC–MS/MS metabolomics to explore the underlying mechanism of UC-MSC treatment for lung fibrosis. Seventy-five mice were allocated into five groups, namely Control, Model, and low/medium/high dose of UC-MSCs groups, and survival metrics, lung morphology, and the levels of the inflammatory cytokines TNF-α, IL-1β, IL-6, and TGF-β1 were subsequently evaluated. Fecal samples from six mice in each of the Control group, Model group, and UC-MSCs-M groups were collected randomly for 16S rDNA sequencing to analyze the gut microbiota and nontargeted metabolomics.

Results

In comparison to IPF model mice, the three treatment groups exhibited increased survival rates, restored alveolar morphology, and reduced levels of the inflammatory cytokines TNF-α, IL-1β, IL-6, and TGF-β1, confirming the anti-inflammatory properties of UC-MSCs in IPF treatment. The findings from the 16S rDNA assay indicate that UC-MSCs treatment effectively lower α-diversity induced such as Chao 1 and ACE, as well as β-diversity, leading to a decrease in microbiota abundance. The findings from the metabolomics analysis revealed that the metabolites exhibiting notable variances were primarily composed of Lipids and lipid-like molecules, Organoheterocyclic compounds, Organic acids and derivatives, and Benzenoids, indicating the potential of UC-MSCs to exert antifibrotic effects via these metabolic pathways.

Conclusion

Umbilical cord-derived mesenchymal stem cells (UC-MSCs) ameliorate bleomycin-induced pulmonary fibrosis symptoms in mice by exerting anti-inflammatory effects and mitigating pulmonary fibrosis through the modulation of gut microbiota disorders and their metabolism. These findings offer novel insights into the potential mechanisms and clinical utility of stem cell therapy for pulmonary fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary FibrosisMetabolomicsFecesRNA, Ribosomal, 16SAnimalsMiceMesenchymal Stem Cell TransplantationMesenchymal Stem CellsGastrointestinal MicrobiomeMaleDNA, RibosomalMice, Inbred C57BLDisease Models, AnimalLungBleomycinMicrobiotaCytokines

Substanzen

RNA, Ribosomal, 16SDNA, RibosomalBleomycinCytokines

Autor:innen und Institutionen

  • Fujian Key Laboratory of Lung Stem Cells, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
  • The Second Clinical Medical School of Fujian Medical University, Quanzhou, Fujian, China.
  • Department of Respiratory and Critical Care Medicine, The Second Hospital of Longyan, Longyan, Fujian, China.
  • Jinan Microecological Biomedicine Shandong Laboratory, Shounuo City Light West Block, Jinan, Shandong, China.
  • Respiratory Medicine Center of Fujian Province, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.

ORCID-Profile: Wenzhao Cheng

Förderung

  • Innovative Research Group Project of the National Natural Science Foundation of China
  • Research Project of Jinan Microecological Biomedicine Shandong Laboratory
  • the Project for Yong and Middle-aged Key Talents in Health Commission of Fujian Province
  • Joint Funds for the innovation of science and Technology of Fujian province

Zitieren

APA

Luo, Y., Zhou, S., Zhang, X., Lin, Y., Liu, J., Cheng, W., & Zeng, Y. (2025). The role of the microbiota and metabolites in the treatment of pulmonary fibrosis with UC-MSCs: Integrating fecal metabolomics and 16S rDNA analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0313989

Vancouver

Luo Y, Zhou S, Zhang X, Lin Y, Liu J, Cheng W, et al. The role of the microbiota and metabolites in the treatment of pulmonary fibrosis with UC-MSCs: Integrating fecal metabolomics and 16S rDNA analysis. PLOS ONE. 2025. doi:10.1371/journal.pone.0313989

BibTeX
@article{Luo2025,
  author = {Luo, Yukai and Zhou, Shuang and Zhang, Xiaojing and Lin, Yijian and Liu, Jun and Cheng, Wenzhao and Zeng, Yiming},
  title = {The role of the microbiota and metabolites in the treatment of pulmonary fibrosis with UC-MSCs: Integrating fecal metabolomics and 16S rDNA analysis},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0313989}
}
Kostenlos starten →